371 related articles for article (PubMed ID: 3134662)
1. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
[No Abstract] [Full Text] [Related]
2. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
Debruyne FM; van der Meijden AP; Franssen MP
Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
[No Abstract] [Full Text] [Related]
3. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
[No Abstract] [Full Text] [Related]
4. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
5. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
6. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
7. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
DeBruyne FM; van der Meijden AP; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg JJ
Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
[TBL] [Abstract][Full Text] [Related]
8. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
Brosman S
Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
[No Abstract] [Full Text] [Related]
9. BCG for bladder cancer.
Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
[No Abstract] [Full Text] [Related]
10. BCG in the management of superficial bladder cancer.
Guinan P; Richardson C; Hanna M; Rubenstein M
Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
[TBL] [Abstract][Full Text] [Related]
11. [Treatment and follow-up of superficial bladder cancer].
Raitanen M
Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
[No Abstract] [Full Text] [Related]
12. Intravesical chemotherapy.
Prout GR
Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
[No Abstract] [Full Text] [Related]
13. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
Barreto L; Csizer Z; Sparkes JD
Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
[TBL] [Abstract][Full Text] [Related]
14. BCG vaccine in urinary bladder cancer.
Brosman SA
West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
[No Abstract] [Full Text] [Related]
15. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study.
Lamm DL; Crissmann J; Blumenstein B; Crawford ED; Montie J; Scardino P; Grossman HB; Stanisic T; Smith J; Sullivan J
Prog Clin Biol Res; 1989; 310():263-70. PubMed ID: 2672016
[No Abstract] [Full Text] [Related]
17. Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
Lamm DL; Sarodosy MS; DeHaven JI
Prog Clin Biol Res; 1989; 310():301-10. PubMed ID: 2672018
[No Abstract] [Full Text] [Related]
18. Treatment modalities in superficial bladder cancer.
Irwin R; Zincke H; Droller MJ; Prout GR; Soloway MS
Semin Urol; 1989 Feb; 7(1 Suppl 1):1-12. PubMed ID: 2499916
[No Abstract] [Full Text] [Related]
19. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
20. BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial.
Fisher HA
Prog Clin Biol Res; 1989; 310():275-83. PubMed ID: 2505271
[No Abstract] [Full Text] [Related]
[Next] [New Search]
